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a bs t r ac t
BACKGROUND

Hereditary angioedema with C1 inhibitor deficiency is characterized by recurrent, unpredictable swelling episodes caused by uncontrolled plasma kallikrein generation and excessive bradykinin release resulting from cleavage of high-molecular-weight kininogen. Lanadelumab (DX-2930) is a new kallikrein inhibitor with the potential for prophylactic
treatment of hereditary angioedema with C1 inhibitor deficiency.
METHODS

We conducted a phase 1b, multicenter, double-blind, placebo-controlled, multiple-ascending-dose trial. Patients with hereditary angioedema with C1 inhibitor deficiency were randomly assigned in a 2:1 ratio to receive either lanadelumab (24 patients) or placebo (13 patients), in two administrations 14 days apart. Patients assigned to lanadelumab were enrolled
in sequential dose groups: total dose of 30 mg (4 patients), 100 mg (4 patients), 300 mg
(5 patients), or 400 mg (11 patients). The pharmacodynamic profile of lanadelumab was
assessed by measurement of plasma levels of cleaved high-molecular-weight kininogen, and
efficacy was assessed by the rate of attacks of angioedema during a prespecified period (day
8 to day 50) in the 300-mg and 400-mg groups as compared with the placebo group.
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RESULTS

No discontinuations occurred because of adverse events, serious adverse events, or deaths
in patients who received lanadelumab. The most common adverse events that emerged during treatment were attacks of angioedema, injection-site pain, and headache. Dose-proportional increases in serum concentrations of lanadelumab were observed; the mean elimination half-life was approximately 2 weeks. Lanadelumab at a dose of 300 mg or 400 mg
reduced cleavage of high-molecular-weight kininogen in plasma from patients with hereditary angioedema with C1 inhibitor deficiency to levels approaching that from patients
without the disorder. From day 8 to day 50, the 300-mg and 400-mg groups had 100% and
88% fewer attacks, respectively, than the placebo group. All patients in the 300-mg group
and 82% (9 of 11) in the 400-mg group were attack-free, as compared with 27% (3 of 11)
in the placebo group.
CONCLUSIONS

In this small trial, administration of lanadelumab to patients with hereditary angioedema
with C1 inhibitor deficiency reduced cleavage of high-molecular-weight kininogen and
attacks of angioedema. (Funded by Dyax; ClinicalTrials.gov number, NCT02093923.)
n engl j med 376;8
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ereditary angioedema with C1 inhibitor deficiency is a rare genetic disease that is characterized by recurrent
swelling episodes, typically affecting the subcutaneous or submucosal tissues of the hands and
feet, abdomen, face, larynx, or genitourinary
tract.1 Swelling of the larynx can be life-threatening because of the risk of asphyxiation.2 The
disease is caused by a deficiency or dysfunction
of C1 inhibitor, a key regulator of the complement, coagulation, and kallikrein–kinin cascades.
In hereditary angioedema with C1 inhibitor deficiency, activation of the kallikrein–kinin cascade leads to uncontrolled generation of plasma
kallikrein and consequent proteolysis of highmolecular-weight kininogen. This results in excessive bradykinin production, which causes vasodilatation, vascular leakage, and subsequent
angioedema and pain.3
All patients with hereditary angioedema with
C1 inhibitor deficiency must have ready access to
an on-demand medication for treatment of acute
attacks.4-6 In addition, some patients benefit from
prophylactic treatment, on the basis of a variety
of criteria, including the frequency and severity
of attacks, a history of airway swelling, and patient preference.4-6 Currently approved prophylactic therapies include attenuated androgens
(e.g., danazol) and a plasma-derived C1 inhibitor
(Cinryze, Shire). Although both treatments significantly reduce the frequency and severity of
attacks,7,8 they have potential shortcomings. Androgens are daily medications and may have side
effects; studies indicate that approximately 25%
of patients with hereditary angioedema with C1
inhibitor deficiency who receive androgens discontinue them owing to unacceptable side effects.9-12 The C1 inhibitor is administered intravenously every 3 to 4 days, which is difficult for
some patients, and carries a theoretical risk of
infection and loss of venous access owing to
repetitive administration. Neither attenuated androgens nor the C1 inhibitor prevents all attacks
of angioedema. Although on-demand treatments,
if administered at the beginning of an attack,
usually halt the attack and shorten the time to
symptom resolution, patients may still have disruptions to their daily activities and anxiety associated with the unpredictable and life-threatening nature of the attacks. Thus, despite
several new therapies, the burden of disease in
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hereditary angioedema with C1 inhibitor deficiency remains high, with a substantial negative
effect on quality of life.13-15
Lanadelumab (DX-2930) is a recombinant, fully
human immunoglobulin monoclonal antibody
inhibitor of kallikrein that has potential for
prophylactic treatment of hereditary angioedema
with C1 inhibitor deficiency.16,17 We report findings from a phase 1b trial evaluating this new
drug for the long-term prevention of attacks of
angioedema.

Me thods
Trial Design

This was a phase 1b, multicenter, randomized,
double-blind, placebo-controlled, multiple-ascending-dose trial of subcutaneous administrations
of lanadelumab in patients with hereditary angioedema with C1 inhibitor deficiency. The objectives were to assess safety and side-effect profile,
characterize the pharmacokinetic and pharmacodynamic characteristics, and evaluate the immunogenicity of multiple subcutaneous lanadelu
mab administrations. In addition, the frequency of
attacks of angioedema and the use of on-demand
therapy were determined in higher-dose groups.
There were four dose groups (30 mg, 100 mg,
300 mg, and 400 mg), with lanadelumab administered in a staggered, dose-escalating fashion.
Eligible patients were randomly assigned in a 2:1
ratio to receive either the active drug or placebo
within a group. (Additional details on the trial
agents are provided in the Supplementary Appendix, available with the full text of this article
at NEJM.org.) If patients had attacks of angioedema, they followed standard-of-care on-demand
treatment as prescribed by their physician.
The sponsor (Dyax) designed the trial with
input from all the authors. The protocol (available at NEJM.org) was approved by the institutional review board or ethics committee at each
participating institution. All the patients provided written informed consent before enrollment. Data were gathered by trial investigators
and staff in collaboration with the sponsor. The
first and subsequent drafts of the manuscript
were written by the first two authors. All the
authors reviewed and edited the manuscript and
made the decision to submit it for publication.
Editorial and technical support in the prepara-
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tion of the manuscript was provided by a professional medical writer at Dyax and by Excel Scientific Solutions. All the authors contributed to
data interpretation and had access to the full
data (nondisclosure agreements were in place).
The authors vouch for the integrity and completeness of the data and all analyses and for
adherence of the trial to the protocol. Statistical
analyses were performed by ICON.
Patient Recruitment

Patients were at least 18 years of age and had a
documented diagnosis of type I or II hereditary
angioedema with C1 inhibitor deficiency, with
the diagnosis based on their meeting all the following criteria: a clinical history consistent with
hereditary angioedema with C1 inhibitor deficiency, a C1 inhibitor antigen or functional level
less than 40% of the normal level (patients with
a C1 inhibitor antigen or functional level 40 to
50% of the normal level could be enrolled if they
also had a C4 level below the normal range and a
family history consistent with type I or II hereditary angioedema with C1 inhibitor deficiency),
and an age at reported onset of first angioedema
symptoms of 30 years or younger or a family
history consistent with type I or II hereditary
angioedema with C1 inhibitor deficiency. Patients
must have had two or more attacks of angioedema per year, with at least one attack in the
previous 6 months. Patients were excluded if
they had received long-term prophylactic medications for hereditary angioedema with C1 inhibitor deficiency in the previous 90 days, used a C1
inhibitor within 7 days before trial enrollment,
had participated in another investigational study
in the previous 90 days, or had exposure within
the previous 5 years to a monoclonal antibody or
recombinant protein bearing an Fc domain.

120 in all four dose groups. (Details are provided in the Supplementary Appendix.)
Efficacy

Prespecified efficacy analyses were performed
on data from patients in the higher-dose lanadel
umab groups (300 mg or 400 mg) or in the
placebo group who had had two or more attacks
of angioedema during the 3 months before enrollment. Thus, the analyses included patients
who had a reasonable probability of having one
or more attacks during the 6-week interval from
day 8 to day 50 (primary efficacy analysis population). The primary efficacy end point was the
number of attacks of angioedema per week from
day 8 to day 50. A post hoc modified intentionto-treat efficacy analysis was performed that
excluded two patients. One patient prematurely
discontinued the trial after one dose, and the
other patient was found after trial enrollment
not to have met the criteria for hereditary angioedema with C1 inhibitor deficiency (C1 inhibitor
testing was not consistent with type I or II hereditary angioedema despite historical laboratory
tests indicating otherwise). (For a discussion of
the patients’ removal, see the Supplementary Appendix.)
Safety

Safety variables were adverse events, including
serious adverse events; vital signs (blood pressure while the patient was sitting or in the supine position, heart rate, oral body temperature,
and respiratory rate); physical examination; clinical laboratory testing (hematologic measurements, clinical chemical analyses, coagulation
tests, and urinalysis); 12-lead electrocardiography; and plasma levels of antidrug antibodies
(details of safety variables are provided in the
Supplementary Appendix).

Blood Sampling and Pharmacokinetic
and Pharmacodynamic Analyses

Statistical Analysis

Blood was obtained from patients with hereditary angioedema with C1 inhibitor deficiency
and from healthy controls to assess the C4 level,
C1 inhibitor antigen and functional level, and
level of antidrug antibody and for pharmacokinetic and pharmacodynamic analyses. Samples
were obtained before administration of each dose
of lanadelumab or placebo (days 1 and 15) and
on days 2, 4, 8, 16, 18, 22, 29, 36, 50, 64, 92, and

Statistical analysis and programming of tables
were performed with the use of SAS software
(SAS Institute). We analyzed rates of attacks of
angioedema using a mixed model of repeated
measurements with the assumption of a Poisson
distribution and using the baseline attack rate as
a covariate. Missing data were not imputed. For
additional details on the statistical analyses, see
the Supplementary Appendix.
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R e sult s
Baseline Characteristics of the Patients

A total of 37 patients with hereditary angioedema
with C1 inhibitor deficiency were randomly assigned to one of five groups (four lanadelumab
dose groups and a placebo group). The majority
of the patients were women (62%), although the
300-mg group had a higher percentage of men
than women (80% vs. 20%). The mean age was
39.9 years (range, 18 to 71). All the patients were
white, and 1 identified as Hispanic or Latino.
Patient characteristics are shown in Table 1. The
mean number of attacks of angioedema in the
previous 3 months was similar in patients who
received lanadelumab and those who received
placebo, as was the number of attacks in the
previous 12 months. A total of 84% of the patients had a diagnosis of type I hereditary angioedema, 11% had a diagnosis of type II, and 5%
had an unspecified type (either type I or type II).
Among the 29 patients who had received on-

of
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demand treatment for attacks of angioedema
during the previous 3 months, icatibant (17 patients) was the most common therapy.
Safety

The safety population included all randomly assigned patients who received at least one dose of
lanadelumab or placebo (24 patients received
lanadelumab, and 13 received placebo); this
population was evaluated for safety in all four
dose groups (Table S1 in the Supplementary Appendix). No notable differences in adverse events
were apparent across dose groups. A total of
58% of the patients who received lanadelumab
and 77% of those who received placebo had at
least one adverse event that emerged during treatment (Table 2). Adverse events that occurred in
at least 5 patients overall were attacks of angioedema, injection-site pain, and headache. Rates
of these adverse events were not appreciably
higher among patients who received lanadelu
mab than among those who received placebo.

Table 1. Baseline Characteristics of Patients with Hereditary Angioedema with C1 Inhibitor Deficiency.*

Characteristic

Lanadelumab Dose Group
30 mg
(N = 4)

100 mg
(N = 4)

300 mg
(N = 5)

400 mg
(N = 11)

Total
Lanadelumab
(N = 24)

Placebo
(N = 13)

All
Patients
(N = 37)

Sex — no. (%)
Male

1 (25)

1 (25)

4 (80)

2 (18)

8 (33)

6 (46)

14 (38)

Female

3 (75)

3 (75)

1 (20)

9 (82)

16 (67)

7 (54)

23 (62)

Mean

46.3±15.5

36.3±18.0

33.2±10.0

40.5±14.3

39.3±14.1

41.2±13.7

39.9±13.8

Range

23–55

25–63

22–46

20–68

20–68

18–71

18–71

Mean

7.0±4.2

10.5±6.7

14.8±12.4

35.2±38.8

22.1±29.1

22.7±35.9

22.3±31.2

Range

3–12

5–20

6–36

11–144

3–144

3–140

3–144

Mean

2.0±0.8

3.5±1.7

3.6±3.1

9.5±9.0

6.0±7.0

6.3±8.9

6.1±7.6

Range

1–3

2–5

1–9

3–36

1–36

0–35

0–36

Age — yr

Attacks of angioedema in
the previous 12 mo

Attacks of angioedema in
the previous 3 mo

History of laryngeal attack
— no. (%)
Yes

0

1 (25)

2 (40)

8 (73)

11 (46)

6 (46)

17 (46)

No

4 (100)

3 (75)

3 (60)

3 (27)

13 (54)

7 (54)

20 (54)

*	Plus–minus values are means ±SD.
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Table 2. Summary of Adverse Events.

Event

Total
Lanadelumab
(N = 24)

Lanadelumab Dose Group
30 mg
(N = 4)

100 mg
(N = 4)

300 mg
(N = 5)

Placebo
(N = 13)

All
Patients
(N = 37)

400 mg
(N = 11)

number of patients (percent)
Adverse events that emerged during
treatment*
Attack of angioedema
Injection-site pain

1 (25)

3 (75)

2 (40)

8 (73)

14 (58)

10 (77)

24 (65)

0

3 (75)

1 (20)

5 (45)

9 (38)

9 (69)

18 (49)

1 (25)

2 (50)

0

3 (27)

6 (25)

3 (23)

9 (24)

0

2 (50)

1 (20)

1 (9)

4 (17)

3 (23)

7 (19)

1 (25)

2 (50)

0

4 (36)

7 (29)

5 (38)

12 (32)

1 (25)

2 (50)

0

3 (27)

6 (25)

3 (23)

9 (24)

Headache

0

1 (25)

0

1 (9)

2 (8)

2 (15)

4 (11)

Injection-site erythema

0

0

0

1 (9)

1 (4)

2 (15)

3 (8)

Headache
Treatment-related adverse events†
Injection-site pain

*	An adverse event was considered to have emerged during treatment if the time of onset was after administration of a trial agent through the
day 120 postdose final follow-up visit or, in the event that the time of onset preceded administration of the trial agent, the adverse event in‑
creased in severity during the 120-day postdose follow-up period. Shown are events that occurred in at least five patients during the trial. A
total of 25% of the patients who received lanadelumab and 38% of those who received placebo had a severe adverse event that emerged
during treatment.
†	These events were considered to be related to a trial agent by a trial investigator who was unaware of the trial-group assignments.

A total of 25% of the patients who received lanadelumab and 38% of those who received placebo had a severe adverse event that emerged
during treatment.
A total of 29% of the patients who received
lanadelumab and 38% of those who received
placebo had an adverse event that was considered by trial investigators, who were unaware of
the trial-group assignments, to be treatmentrelated (Table 2). The most common treatmentrelated adverse events were injection-site pain
(occurring in 25% of the patients who received
lanadelumab and in 23% of those who received
placebo) and headache (occurring in 8% of the
patients who received lanadelumab and in 15%
of those who received placebo). Two patients
who received lanadelumab had severe adverse
events that were considered to be treatmentrelated: one patient (in the 30-mg group) had
injection-site pain that lasted for 1 minute, and
another (in the 400-mg group) had worsening
headache and ongoing night sweats. There were
no deaths or discontinuations due to an adverse
event that emerged during treatment and no important safety signals in patients who received
lanadelumab or placebo. There were no serious
adverse events in patients who received lanadel
n engl j med 376;8

umab. One serious adverse event, pneumonia,
occurred on day 87 in one patient who received
placebo.
Antidrug Antibodies

Two of the patients included in the safety analysis were confirmed to be positive for antidrug
antibodies. One patient (30-mg dose group)
tested positive at day 120, and the other patient
(400-mg dose group) tested positive at day 92.
All antidrug antibodies were nonneutralizing.
There was no evidence of loss of pharmacokinetic or pharmacodynamic effect of lanadelumab
in either patient who was positive for antidrug
antibodies.
Pharmacokinetic and Pharmacodynamic
Characteristics

The pharmacokinetic analysis population included all randomly assigned patients with hereditary angioedema with C1 inhibitor deficiency
who received at least one dose of lanadelumab
and had sufficient blood samples (22 patients);
the pharmacodynamic analysis population included these patients plus the 13 patients who
received at least one dose of placebo (total, 35 patients) (Table S1 in the Supplementary Appendix).
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Drug levels of lanadelumab were dose-dependent
and had a prolonged half-life, typical of a human
monoclonal antibody. The maximum plasma
concentration of lanadelumab increased with
increasing dose, and the half-life ranged from
13.8 to 15.0 days (Fig. 1A). In addition, sustained
quantifiable drug concentrations were observed
through day 120 in all lanadelumab dose groups.
These characteristics were consistent with values
obtained in a phase 1a study involving healthy
volunteers.16
Two different methods were used to determine kallikrein activity. A Western blot assay
measured cleaved high-molecular-weight kininogen, the endogenous substrate of kallikrein, as a
biomarker of its activity. Predose plasma across
all patients with hereditary angioedema with C1
inhibitor deficiency when they were asymptomatic (Fig. 1B) contained a mean (±SE) level
of cleaved high-molecular-weight kininogen of
51.0±4.2% (95% confidence interval [CI], 43.6 to
59.9). In contrast, predose samples obtained
from healthy controls without hereditary angioedema with C1 inhibitor deficiency contained a
mean level of cleaved high-molecular-weight
kininogen of 8.3±0.5% (95% CI, 7.2 to 9.4).
Therefore, plasma from patients with hereditary
angioedema with C1 inhibitor deficiency had
higher levels of circulating cleaved high-molecular-weight kininogen than plasma from healthy
controls. No significant differences in mean
levels of cleaved high-molecular-weight kininogen
were observed between the 30-mg dose group or
the 100-mg dose group and the placebo group.
An evaluation of mean plasma levels of
cleaved high-molecular-weight kininogen showed
significant reductions (P<0.05) from predose
levels in the 300-mg and 400-mg dose groups in
samples obtained on day 8 and on day 22.
Maximum reductions in levels of cleaved highmolecular-weight kininogen in the 300-mg and
400-mg dose groups occurred on day 22, which
approximates the time to maximum plasma
concentration of the drug after the second lanadelumab administration. Furthermore, in these
dose groups, the level of cleaved high-molecularweight kininogen approached that observed in
healthy volunteers (8.3±0.5%), which shows the
pharmacodynamic activity of lanadelumab and
suggests its potential to normalize the instability of plasma with respect to excess contact-system activation in patients with hereditary angioedema with C1 inhibitor deficiency. In addition,
722
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lanadelumab suppressed activated factor XII–
mediated increases in the percent of cleaved
high-molecular-weight kininogen in a dosedependent manner (Fig. 1C and 1D).
The pharmacodynamic activity of lanadelu
mab was also evaluated with the use of a fluorogenic assay, which showed dose-dependent
kallikrein inhibition in samples obtained from
patients in the 100-mg, 300-mg, and 400-mg
dose groups (Fig. S1 in the Supplementary Appendix). Minimal levels of inhibition were observed in the 30-mg dose group and in the placebo group. After the second administration of
lanadelumab in the 100-mg, 300-mg, and 400-mg
dose groups, peak inhibition values of approximately 30%, 60%, and 70%, respectively, were
observed. The inhibition was time-dependent
and aligned closely with the plasma concentrations of lanadelumab, findings that suggest that
the effect of lanadelumab treatment correlates
with its biologic activity.
Efficacy

We evaluated the efficacy of lanadelumab by assessing the incidence of attacks of angioedema
among patients with hereditary angioedema with
C1 inhibitor deficiency who were assigned to the
300-mg, 400-mg, and placebo groups and who
received two doses of the trial agent (Table S1 in
the Supplementary Appendix). All the patients
(receiving lanadelumab or placebo) included in
this analysis had a historical baseline attack rate
of 2 or more attacks in the 3 months before
enrollment. The baseline rate of attacks of angioedema per week was 0.33 in the 300-mg
group, 0.55 in the 400-mg group, and 0.39 in the
placebo group (Table 3). With the removal of the
2 patients in the 400-mg group for the modified
intention-to-treat analysis, the rate of attacks did
not change significantly (0.52 attacks per week).
Between day 8 and day 50, all the patients in
the 300-mg group were attack-free, as compared
with 3 of 11 patients (27%) in the placebo group,
representing a rate of attacks per week of 0 versus 0.37 (P<0.001). Nine of 11 patients (82%) in
the 400-mg group were attack-free, representing
a rate of attacks per week (0.05) that was significantly lower than the rate with placebo (P = 0.005).
Patients in the 300-mg group, 400-mg group,
and combined 300-mg and 400-mg groups had
100%, 88%, and 91% fewer attacks, respectively,
than patients in the placebo group. In the post
hoc modified intention-to-treat analysis (exclud-

nejm.org

February 23, 2017

The New England Journal of Medicine
Downloaded from nejm.org at WASHINGTON UNIV SCH MED MEDICAL LIB on February 28, 2017. For personal use only. No other uses without permission.
Copyright © 2017 Massachusetts Medical Society. All rights reserved.

Hereditary Angioedema Prophylaxis

A Plasma Concentration of Lanadelumab

Placebo (N=12 or 13)
30 mg (N=4)
100 mg (N=4)
300 mg (N=5)
400 mg (N=9)

Cmax
t1/2
AUC
(ng/ml) (day×ng/ml) (day)
45,000
40,000
35,000
30,000
25,000
20,000
15,000
10,000
5,000
0

30 mg 3,895
100 mg 7,890
300 mg 27,460
400 mg 45,322

0

20

40

60

14.2
14.6
13.8
15.0

64,100
135,425
451,800
762,778

80

100

Plasma Level of Cleaved HMWK (%)

Concentration of Lanadelumab (ng/ml)

B Percent Cleaved HMWK

100 mg (N=4)
400 mg (N=9)

30 mg (N=4)
300 mg (N=5)

120

100

P= 0.019
P= 0.003

80

P= 0.01
P= 0.002

60
40
Healthy
controls
(8.3%)

20
0

Predose 8

22

50

64

92

120

Day

Day

C Percent Cleaved HMWK after Addition of Activated

D Western Blot Assay

Factor XII

Placebo (N=12 or 13)
30 mg (N=4)
100 mg (N=4)
300 mg (N=5)
400 mg (N=9)

Plasma Level of Cleaved HMWK (%)

P<0.001

100

P= 0.017 P<0.001
P<0.001
P= 0.005
P<0.001

80

Healthy
controls
(58.9%)

60
40

Placebo

400 mg

Patients
with
HAE
(93.4%)

P= 0.001

kDa
— 114
— 56
— 46

Day 1
Activated – +

8

22

1

8

22

– +

– +

– +

– +

– +

20
0

Predose 8

22

50

64

92

120

Day

Figure 1. Pharmacokinetics and Pharmacodynamics of Lanadelumab Administration.
Panel A shows the mean plasma concentration of lanadelumab after subcutaneous injections on day 1 and day 15,
according to dosing group. I bars represent standard errors. The embedded table summarizes pharmacokinetic mea‑
surements. AUC denotes area under the plasma concentration–time curve, Cmax maximum plasma concentration,
and t1/2 half‑life. Panel B shows the mean plasma level of cleaved high‑molecular‑weight kininogen (HMWK) according
to trial group. The dashed line indicates the mean level in 32 healthy controls (8.3±0.5%). Panel C shows the mean
cleaved HMWK levels after ex vivo activation for the contact system through the addition of activated factor XII to
plasma from study patients and healthy controls. The upper dashed line indicates the mean level in predose samples
from 35 patients with hereditary angioedema (HAE) with C1 inhibitor deficiency (93.4±4.0%); the lower dashed line
indicates the mean level in 32 healthy controls (58.9±2.2%). In Panels B and C, the number of participants in the pla‑
cebo group is 12 for predose and day 64 samples and 13 for all other samples, and T bars represent standard errors.
Panel D shows the results of a representative Western blot assay, with intact HMWK at 114 kDa and with cleaved
HMWK observed by means of the HMWK light‑chain bands at 56 kDa and 46 kDa in plasma that was either unacti‑
vated (–) and activated (+) with factor XII. Samples were obtained on day 1 (predose), day 8, and day 22 from a sin‑
gle patient who received lanadelumab at a dose of 400 mg and from a single patient who received placebo.

ing 2 patients in the 400-mg group), the 400-mg 400-mg groups had 97% fewer attacks than the
group had 95% fewer attacks than the placebo placebo group (P<0.001).
group (P = 0.002), and the combined 300-mg and
Table S2 in the Supplementary Appendix
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Table 3. Attacks of Angioedema in the Lanadelumab 300-mg and 400-mg Groups and the Placebo Group.*
Trial Group

At Baseline†

Day 8 to Day 50

1

0.23

0

2

0.15

0

P Value‡

Lanadelumab 300 mg
Patient no. — attacks/wk

3

0.69

0

4

0.23

0

0.33

0

Primary analysis§

NA

100

<0.001

Modified analysis¶

NA

100

<0.001

Patients 1–4
Mean attacks/wk
Relative decrease vs. placebo in rate of attacks — %

Lanadelumab 400 mg
Patient no. — attacks/wk
5

0.31

0

6

0.23

0

7

0.69

0

8

0.62

0

9

0.62

0.33

10

2.77

0
0.17

11

0.46

12

0.69

0

13

0.46

0

14

0.69

0

15

0.46

0

0.55

0.05

Primary analysis§

NA

88

0.005

Modified analysis¶

NA

95

0.002

0.23

0

Patients 5–15
Mean attacks/wk
Relative decrease vs. placebo in rate of attacks — %

Placebo
Patient no. — attacks/wk
16

724

17

0.31

0.67

18

0.46

0.67

19

2.69

0.67

20

0.23

1.50

21

0.31

0.33

22

0.46

0.17

23

0.54

0.33

24

0.23

0.17

25

0.23

0

26

0.54

0
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Table 3. (Continued.)
Trial Group

At Baseline†

Day 8 to Day 50

0.39

0.37

Mean attacks/wk in patients 16–26

P Value‡

*	Only patients who had had at least two attacks of angioedema in the 3 months before enrollment were included. NA
denotes not applicable.
†	Baseline was defined as the 3 months before day 1 of dosing.
‡	The P value is for the comparison with placebo from day 8 to day 50.
§	The result is based on general estimating equation (GEE) analysis of repeated counts per week during the observation
period (days 8 to 50). The baseline rate of attacks of angioedema per week is a covariate, trial group is a fixed effect, and
trial participant is a random effect in the GEE model with an independent working correlation structure. The observed
rate of attacks per week was 0% in the 300-mg group, and thus an arbitrarily small value (0.000001) was imputed for
the variable of the rate of attacks for a random patient in the 300-mg group at week 2 to enable the GEE analysis to
converge.
¶	Two patients in the 400-mg group were excluded from the modified efficacy analysis: one patient who received only one
dose of lanadelumab and was subsequently lost to follow-up and one patient who did not have type I or II hereditary
angioedema.

shows the characteristics of attacks of angioedema (location, severity, and on-demand treatment) that occurred during the period from day
8 to day 50 in patients with hereditary angioedema with C1 inhibitor deficiency who were
included in the prespecified primary efficacy
analysis. These data suggest a consistent response
to treatment, regardless of baseline severity. The
moderate and severe attacks that occurred in
the patient who received only one dose of lanadelumab (and was therefore not included in the
modified intention-to-treat efficacy analysis) are
included in that table.
Figure 2A shows the incidence of attacks of
angioedema during the trial period among patients who received placebo. We next examined
the relationship between lanadelumab drug exposure and the incidence of attacks. In order to
correlate drug exposure and the incidence of
attacks, the mean plasma concentrations of lanadelumab were plotted against the days when attacks occurred in the 300-mg and 400-mg groups
(Fig. 2B and 2C). During the primary efficacy
window (day 8 to day 50), the incidence of attacks decreased among patients who received
lanadelumab at a dose of 300 mg or 400 mg,
with attacks reemerging when the drug concentration decreased. The one attack that occurred
during the efficacy period was a mild peripheral
attack that resolved within 8 hours without treatment. Although the 30-mg and 100-mg groups
were not included in the primary analysis population, the incidence of attacks also decreased in
these groups (Fig. S2 in the Supplementary Appendix).
n engl j med 376;8

Discussion
This 6-week phase 1b trial involving patients
with hereditary angioedema with C1 inhibitor
deficiency suggests that two administrations of
lanadelumab 14 days apart are safe at a total
dose of up to 400 mg. In the primary efficacy
and modified intention-to-treat analyses, two
administrations of lanadelumab at a total dose
of 300 mg or 400 mg appeared to be effective in
preventing attacks of angioedema, resulting in
100% and 88% fewer attacks, respectively, than
the number of attacks with placebo. The pharmacokinetic profile of lanadelumab was linear and
dose-dependent and had a prolonged half-life of
approximately 14 days, typical of a human monoclonal antibody. The decrease in attacks of angioedema strongly correlated with drug exposure,
which corroborated the results of the efficacy
analysis. In addition, pharmacodynamic results
confirmed kallikrein inhibition in a dose-dependent and time-dependent manner. Results from
the Western blot assay suggested the potential to
normalize levels of cleaved high-molecular-weight
kininogen to those of healthy controls after
doses of 300 mg or greater. We believe that the
observed effects of lanadelumab, both the pharmacodynamic characteristics and the decrease
in the rate of attacks, provide proof of concept
that lanadelumab has the potential to correct
the pathophysiological abnormality underlying
attacks of angioedema and may be a new therapeutic option for hereditary angioedema with C1
inhibitor deficiency.
Unregulated kallikrein is a key pathophysio-
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validated through the effectiveness of ecallantide (Kalbitor, Dyax), which specifically targets
Primary efficacy period
kallikrein.18 The Western blot biomarker assay
(day 8–50)
Attack of angioedema
measuring cleaved high-molecular-weight kininogen provides evidence that lanadelumab causes
a dose-dependent decrease of kallikrein activity
−20
0
20
40
60
80
100
120
in patients with hereditary angioedema with C1
inhibitor deficiency. At baseline, patients with
Day
hereditary angioedema with C1 inhibitor defiB Lanadelumab, 300 mg
ciency had elevated plasma levels of cleaved highPrimary efficacy period
(day 8–50)
molecular-weight kininogen; this finding is simi50,000
lar to those of previous reports.19 To minimize
300 mg (N=5)
Attack of angioedema
intersite variability, all sites obtained and pro40,000
cessed plasma in a standardized fashion and
added protease inhibitors to minimize cleavage
30,000
(Fig. S3 in the Supplementary Appendix).19,20
The 300-mg and 400-mg doses reduced cleaved
20,000
high-molecular-weight kininogen in both unactivated and activated factor XII samples to levels
10,000
approaching those observed in healthy controls.
0
In addition, the activity of lanadelumab, evalu−40 −20
0
20
40
60
80
100 120
ated with the use of the fluorogenic assay,
Day
showed dose-dependent kallikrein inhibition in
samples collected from the 100-mg, 300-mg,
C Lanadelumab, 400 mg
Primary efficacy period
and 400-mg dose groups (Fig. S1 in the Supple(day 8–50)
50,000
mentary Appendix). Collectively, these results
400 mg (N=9)
show the activity of lanadelumab and suggest its
Attack of angioedema
40,000
ability to potentially normalize the instability of
plasma with respect to excess contact-system
30,000
activation in patients with hereditary angioedema
with C1 inhibitor deficiency. Furthermore, the
20,000
reduction in attacks of angioedema observed
during periods of high drug exposure suggests
10,000
that prolonged inhibition of kallikrein is an effective prophylactic approach to hereditary angio0
−40 −20
0
20
40
60
80
100 120
edema with C1 inhibitor deficiency.
Day
This phase Ib trial supports the continued
investigation of lanadelumab. No patients disFigure 2. Mean Pharmacokinetic Plots and Reduction in Frequency of Attacks
continued the trial because of adverse events,
of Angioedema between Days 8 and 50.
and the low incidence and severity of adverse
Panel A shows the incidence of attacks of angioedema in the placebo group
events and the type of events did not indicate a
during the trial period. The trial agents (lanadelumab or placebo) were ad‑
ministered on day 1 and on day 15. Panels B and C are graphs of the mean
safety signal. Fletcher factor deficiency, a condiplasma concentration of lanadelumab (blue circles) overlaid with the incidence
tion characterized by a severe congenital defiof attacks in the lanadelumab 300-mg or 400-mg dose group. Two patients in
ciency of prekallikrein, suggests limited risk
the 400-mg group were excluded from the modified efficacy analysis: one pa‑
from long-term kallikrein inhibition, since there
tient who received only one dose of lanadelumab and was subsequently lost to
are no obvious clinical complications directly
follow-up and one patient who did not have type I or II hereditary angioedema.
attributable to the defect.21-24 Although the efficacy results of this trial are encouraging, the
duration of the trial was relatively short. A phase 3
logical defect that is responsible for the develop- trial evaluating the safety and efficacy of 6 months
ment of attacks of angioedema, and the impor- of lanadelumab treatment is under way (Clinicaltance of kallikrein as a drug target has been Trials.gov number, NCT02586805).
Concentration of Lanadelumab (ng/ml)

Concentration of Lanadelumab (ng/ml)
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